Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker SPRO
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | Esther Rajavelu See Remarks, Director | SPRO Spero Therapeutics, Inc. | Sale | 40,851 | $1.04 | $42.5K Sale | Form 4 ↗ |
| May 4, 2026 | Esther Rajavelu See Remarks | SPRO Spero Therapeutics, Inc. | Sale | 25,240 | $2.51 | $63.4K Sale | Form 4 ↗ |
| Feb 6, 2026 | Esther Rajavelu See Remarks | SPRO Spero Therapeutics, Inc. | Sale | 50,816 | $2.36 | $119.9K Sale | Form 4 ↗ |
| Feb 6, 2026 | Esther Rajavelu See Remarks | SPRO Spero Therapeutics, Inc. | Sale | 37,101 | $2.36 | $87.6K Sale | Form 4 ↗ |
| Feb 6, 2026 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 18,652 | $2.36 | $44.0K Sale | Form 4 ↗ |
| Feb 4, 2026 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 3,471 | $2.24 | $7,775 Sale | Form 4 ↗ |
| Feb 3, 2026 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 24,224 | $2.14 | $51.8K Sale | Form 4 ↗ |
| Feb 2, 2026 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 18,891 | $2.20 | $41.6K Sale | Form 4 ↗ |
| Feb 2, 2026 | Esther Rajavelu See Remarks | SPRO Spero Therapeutics, Inc. | Sale | 18,442 | $2.20 | $40.6K Sale | Form 4 ↗ |
| Nov 7, 2025 | Esther Rajavelu See Remarks | SPRO Spero Therapeutics, Inc. | Sale | 40,270 | $2.37 | $95.4K Sale | Form 4 ↗ |
| Aug 28, 2025 | Ankit Mahadevia Director | SPRO Spero Therapeutics, Inc. | Sale | 6,572 | $1.97 | $12.9K Sale | Form 4 ↗ |
| Aug 28, 2025 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 1,695 | $1.97 | $3,339 Sale | Form 4 ↗ |
| Feb 5, 2025 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 24,920 | $0.78 | $19.4K Sale | Form 4 ↗ |
| Feb 5, 2025 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 27,643 | $0.78 | $21.6K Sale | Form 4 ↗ |
| Feb 5, 2025 | Timothy Keutzer Chief Operating Officer | SPRO Spero Therapeutics, Inc. | Sale | 3,974 | $0.78 | $3,100 Sale | Form 4 ↗ |
| Feb 5, 2025 | Esther Rajavelu CFO & CBO | SPRO Spero Therapeutics, Inc. | Sale | 20,689 | $0.78 | $16.1K Sale | Form 4 ↗ |
| Feb 5, 2025 | Sath Shukla CEO & President | SPRO Spero Therapeutics, Inc. | Sale | 106,408 | $0.78 | $83.0K Sale | Form 4 ↗ |
| Feb 5, 2025 | Sath Shukla CEO & President | SPRO Spero Therapeutics, Inc. | Sale | 42,786 | $0.78 | $33.4K Sale | Form 4 ↗ |
| Feb 5, 2025 | Sath Shukla CEO & President | SPRO Spero Therapeutics, Inc. | Sale | 6,139 | $0.78 | $4,788 Sale | Form 4 ↗ |
| Feb 5, 2025 | Ankit Mahadevia Director | SPRO Spero Therapeutics, Inc. | Sale | 55,260 | $0.78 | $43.1K Sale | Form 4 ↗ |
| Feb 5, 2025 | Ankit Mahadevia Director | SPRO Spero Therapeutics, Inc. | Sale | 13,959 | $0.78 | $10.9K Sale | Form 4 ↗ |
| Nov 8, 2024 | Esther Rajavelu CFO & CBO | SPRO Spero Therapeutics, Inc. | Sale | 17,245 | $1.30 | $22.4K Sale | Form 4 ↗ |
| Nov 7, 2024 | Esther Rajavelu CFO & CBO | SPRO Spero Therapeutics, Inc. | Sale | 23,351 | $1.31 | $30.6K Sale | Form 4 ↗ |
23 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:29 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances